Detail akcie Camurus online

Business Summary: Camurus AB is a Sweden-based research and development based pharmaceutical and biotechnology company with a focus on the development and marketing of specialty medicines, providing patients suffering from severe and chronic disease, such as opioid dependence, pain, cancer, and endocrine diseases. The Company has a diversified research portfolio, which includes products in clinical trials. The Company’s products are based on FluidCrystal formulation technology. FluidCrystal is Company's patent-protected technology platform. Camurus AB is the parent company of the Group, which comprises of legal entities, namely: Camurus Inc, Cubosome Inc, Development AB, Camurus GmbH, Camurus Ltd, Camurus Oy, Camurus AS, Camurus SAS, Camurus Pty Ltd, Camurus S.L, Camurus ApS, Camurus BV and Camurus Austria GmbH.
Financial Summary: BRIEF: For the six months ended 30 June 2024, Camurus AB revenues decreased 13% to SEK834.9M. Net income decreased 58% to SEK152.1M. Revenues reflect Milestone payments segment decrease from SEK369.7M to SEK0K, Licensing revenues segment decrease of 81% to SEK267K, North America segment decrease of 81% to SEK70.8M. Net income also reflects Research and development costs increase of 36% to SEK353.6M (expense).